These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14714702)

  • 1. Pharmacogenomics, genetic tests, and patent-based incentives.
    Meurer MJ
    Adv Genet; 2003; 50():399-426; discussion 507-10. PubMed ID: 14714702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.
    Garrison LP; Carlson RJ; Carlson JJ; Kuszler PC; Meckley LM; Veenstra DL
    Drug Metab Rev; 2008; 40(2):377-401. PubMed ID: 18464050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do patents impede the provision of genetic tests in Australia?
    Nicol D; Liddicoat J
    Aust Health Rev; 2013 Jun; 37(3):281-5. PubMed ID: 23702081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory approval for new pharmacogenomic tests: a comparative overview.
    Joly Y; Koutrikas G; Tassé AM; Issa A; Carleton B; Hayden M; Rieder MJ; Ramos-Paque E; Avard D
    Food Drug Law J; 2011; 66(1):1-24, i. PubMed ID: 24505844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
    Barton JH; Emanuel EJ
    JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging ethical issues in pharmacogenomics: from research to clinical practice.
    Freund CL; Wilfond BS
    Am J Pharmacogenomics; 2002; 2(4):273-81. PubMed ID: 12421098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of pharmacogenomics into the community pharmacy: billing considerations.
    O'Connor SK; Michaels N; Ferreri S
    Pharmacogenomics; 2015; 16(3):175-80. PubMed ID: 25712181
    [No Abstract]   [Full Text] [Related]  

  • 8. An economic justification for open access to essential medicine patents in developing countries.
    Flynn S; Hollis A; Palmedo M
    J Law Med Ethics; 2009; 37(2):184-208. PubMed ID: 19493066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the US Patent System on the promise of personalized medicine.
    Solomon LM; Sieczkiewicz GJ
    Gend Med; 2007 Sep; 4(3):187-92. PubMed ID: 18022586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic testing, ethical concerns, and the role of patent law.
    Caulfield TA; Gold ER
    Clin Genet; 2000 May; 57(5):370-5. PubMed ID: 10852371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct to confusion: lessons learned from marketing BRCA testing.
    Matloff E; Caplan A
    Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will pharmacogenomics alter the role of patents in drug development?
    Eisenberg RS
    Pharmacogenomics; 2002 Sep; 3(5):571-4. PubMed ID: 12223043
    [No Abstract]   [Full Text] [Related]  

  • 14. Ethical and public policy challenges for pharmacogenomics.
    Gershon ES; Alliey-Rodriguez N; Grennan K
    Dialogues Clin Neurosci; 2014 Dec; 16(4):567-74. PubMed ID: 25733960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From intellectual property to commercial property].
    Cappelaere P
    Bull Cancer; 2005 Apr; 92(4):297-8. PubMed ID: 15888384
    [No Abstract]   [Full Text] [Related]  

  • 16. Finding a liability-free space in which personalized medicine can bloom.
    Evans BJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):461-5. PubMed ID: 17713468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal, ethical, and conceptual bottlenecks to the development of useful genomic tests.
    Tomasson M
    Ann Health Law; 2009; 18(2):231-60, 8 p. preceding i. PubMed ID: 21950240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent ruling expands access to genetic tests and treatments.
    Woodward C
    CMAJ; 2013 Aug; 185(11):E507-8. PubMed ID: 23798460
    [No Abstract]   [Full Text] [Related]  

  • 19. Israeli doctors want to stop European patent for genetic test.
    Siegel-Itzkovich J
    BMJ; 2005 Jul; 331(7507):8. PubMed ID: 15994669
    [No Abstract]   [Full Text] [Related]  

  • 20. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.